Precipio, Inc. (PRPO)

$1.16

+0.04 (+3.57%)
Rating:
Recommendation:
Buy
Symbol PRPO
Price $1.16
Beta 2.281
Volume Avg. 0.27M
Market Cap 26.342M
Shares () -
52 Week Range 0.91-4.65
1y Target Est -
DCF Unlevered PRPO DCF ->
DCF Levered PRPO LDCF ->
ROE -46.73% Strong Sell
ROA -41.71% Strong Sell
Operating Margin -
Debt / Equity 25.75% Neutral
P/E -
P/B 1.19 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest PRPO news


Ilan Danieli
Healthcare
Diagnostics & Research
NASDAQ Capital Market

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.